theralugand

Theralugand is a radiopharmaceutical precursor consisting of non-carrier-added lutetium-177 chloride ([177Lu]Lutetium Chloride) in solution, produced to GMP standards. It is not intended for direct use in patients but is used exclusively for the radiolabelling of carrier molecules that have been specifically developed and authorized for labeling with lutetium-177 chloride. The active substance, lutetium-177, is a radioactive isotope emitting beta-minus and gamma radiation. When attached to appropriate carrier medicines (such as peptides or antibodies), it enables targeted radionuclide therapy—most notably in cancer indications like neuroendocrine tumors and metastatic prostate cancer. The clinical effect depends on the nature of the labeled carrier molecule; Theralugand itself serves only as the source of radioisotope for these therapies[1][5][6][7]. Developed by Eckert & Ziegler Radiopharma GmbH, Theralugand has received marketing authorization across all countries in the European Economic Area (EEA) as of November 2024[3][9]. It is supplied as a sterile solution at 40 GBq/mL concentration and must be handled according to strict radiation safety protocols.

Brand names

Theralugand

Other names

lutetium-177 chloridelutetium177 chloridelutetium 177 chloriden.c.a. lutetium-177Lu-177Lu177Lu 177lutetium (177Lu) chloridelutetium-177-Eckert & Ziegler Radiopharma-therapeutic radionuclide (beta emitter)